News – Page 929 – Endpoints News

Backed by Novo and OrbiMed, Thierry Abribat hauls in $75M for biotech #3 — a transatlantic upstart focused on rare ...

6 years ago

Move over, Hong Kong: Shanghai’s new tech board sees fervent demand for maiden biotech IPO

6 years ago

Salk scientists create the world’s first human/monkey chimeras in China — cue the controversy

6 years ago

Korean biotech sees shares blitzed as its oncolytic virus/Nexavar combo fizzles in liver cancer

6 years ago

BioMarin execs make their case for hemophilia gene therapy as fretful analysts start to hedge their bets

6 years ago

At newly rechristened Rakuten Medical, Japanese billionaire Mikitani ups the ante with another megaround

6 years ago

Adrian Hayday refutes challenge on influential autoantibody paper by Karolinska scientists

6 years ago

Amicus touts latest set of gene therapy data; Novo Nordisk expands discovery deal for diabetes

6 years ago

Jumping into growing queue of buyers, Vertex chief targets a slate of new and 'larger' deals ahead

6 years ago

PD-L1, CD47 and now CD24? Star Stanford I/O scientist Irv Weissman points to a ‘major’ new cancer target

6 years ago

FDA-EMA workshop discusses quality challenges for PRIME, breakthrough therapies

6 years ago

Adaptimmune R&D chief Amado hits the exit amid a top-level shakeup as new CEO tries to revive ebbing enthusiasm

6 years ago

Fresh delay for $4.3B Roche/Spark deal triggers analyst concerns about gene therapy M&A

6 years ago

Still trailing far behind a blockbuster rival, Novartis gathers another round of positive survival data for Kisqali

6 years ago

Arie Belldegrun and the crew at Vida reap a $600M harvest for fund II — and they've got LA in their sights

6 years ago

Atlantic Healthcare's drug fails late-stage test; Translate Bio breaks out early CF data

6 years ago

FDA chief backs 2 new pathways to spur drug importation — but analysts shrug it all off

6 years ago

Merck's Keytruda makes the cut as a second-line monotherapy for certain esophageal cancer patients

6 years ago

Gilead chief Daniel O’Day isn’t done making headlines — with more R&D deals and lots of new hires to come

6 years ago

Amarin boosted as another milestone to the FDA’s big Vascepa decision flies by with no sign of an AdCom

6 years ago

Novartis' $18.5B in M&A under Vas Narasimhan says a lot about their careful — but opportunistic — deal strategy

6 years ago

Pedal to the metal, Amgen finally has a hot new drug star on its hands — and they have some news

6 years ago

Bayer, Orion win speedy approval for prostate cancer drug darolutamide

6 years ago

Wellington Partners tanks up with $237M for its next life sci fund — same strategy, but with more cash on hand

6 years ago

First page Previous page 926 927 928929930 931 932 Next page Last page